{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sada R"],"funding":["Japan Agency for Medical Research and Development"],"pagination":["3358-3369"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11447883"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["115(10)"],"pubmed_abstract":["Cytoskeleton-associated protein 4 (CKAP4) is a cell surface receptor for Dickkopf 1 (DKK1), a secreted protein. The DKK1-CKAP4 pathway is activated in various malignant tumors, including pancreatic, lung, esophageal, and liver cancers, to promote tumor growth. Thus, CKAP4 has been expected to represent a novel molecular target of cancer therapy. Recombinant mouse anti-CKAP4 antibodies were generated based on an original mouse antibody (3F11-2B10) and inhibited DKK1-CKAP4 signaling and xenograft tumor formation induced by pancreatic cancer cells, which was comparable with 3F11-2B10. From the 3F11-2B10 nucleotide sequence, humanized anti-CKAP4 antibody (Hv1Lt1) was subsequently developed. The binding affinity of Hv1Lt1 for CKAP4 was superior to that of 3F11-2B10. Hv1Lt1 inhibited DKK1 bindin"],"journal":["Cancer science"],"pubmed_title":["Newly developed humanized anti-CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1-CKAP4 signaling."],"pmcid":["PMC11447883"],"funding_grant_id":["JP21ym0126039","JP22ama221001","JP22ym0126039","JP23ym0126039"],"pubmed_authors":["Matsumoto S","Kikuchi A","Yamamoto H","Sada R","Harada A"],"additional_accession":[]},"is_claimable":false,"name":"Newly developed humanized anti-CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1-CKAP4 signaling.","description":"Cytoskeleton-associated protein 4 (CKAP4) is a cell surface receptor for Dickkopf 1 (DKK1), a secreted protein. The DKK1-CKAP4 pathway is activated in various malignant tumors, including pancreatic, lung, esophageal, and liver cancers, to promote tumor growth. Thus, CKAP4 has been expected to represent a novel molecular target of cancer therapy. Recombinant mouse anti-CKAP4 antibodies were generated based on an original mouse antibody (3F11-2B10) and inhibited DKK1-CKAP4 signaling and xenograft tumor formation induced by pancreatic cancer cells, which was comparable with 3F11-2B10. From the 3F11-2B10 nucleotide sequence, humanized anti-CKAP4 antibody (Hv1Lt1) was subsequently developed. The binding affinity of Hv1Lt1 for CKAP4 was superior to that of 3F11-2B10. Hv1Lt1 inhibited DKK1 bindin","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-01T07:32:04.43Z","creation":"2025-04-19T19:32:00.012Z"},"accession":"S-EPMC11447883","cross_references":{"pubmed":["39118263"],"doi":["10.1111/cas.16278"]}}